Just a year after picking the first targets for its artificial intelligence-based drug discovery platform, Generate Biomedicines has already taken its first product candidate into the clinic, and it now plans to use a new financing round to advance more, with the potential to have as many as half a dozen candidates in human trials during the next two years.
AI-Fueled Generate Maps Out Path To Clinic Over Next 24 Months
The biotech company already has a candidate with a tough target in the clinic for COVID-19 and plans to have four to six candidates in the clinic over the next two years following a $273m series C round.
